Characteristics of Fetuses and Image-Derived Dosimetry Results
| Fetus | Stage of gestation | Mother’s weight (kg) | Injected activity (MBq) | Machine | Phantom (trimester) | Fraction | Time-integrated activity (Bq h/Bq) | Dose, Olinda 1 (mGy/MBq) | Dose, Olinda 2 (mGy/MBq) | Reference |
| 1 | 5 wk | 86 | 296 | PET/CT | Nonpregnant | 0.0012 | 0.0030 | 1.73E–02 | 1.92E–02 | (4) |
| 2 | 6 wk | 68 | 583 | PET | Nonpregnant | 0.0036 | 0.0095 | 3.14E–02 | 3.29E–02 | (1) |
| 3 | 8 wk | 60 | 320 | PET/CT | Nonpregnant | 0.0020 | 0.0053 | 2.23E–02 | 2.39E–02 | (5) |
| 4 | 10 wk | 71 | 296 | PET/CT | Nonpregnant | 0.0018 | 0.0046 | 2.08E–02 | 2.26E–02 | (6) |
| 5 | 12 wk | 58 | 385 | PET/CT | 1 | 0.0006 | 0.0016 | 7.25E–03 | 1.17E–02 | (4) |
| 6 | ∼12 wk | 77 | 350 | PET | 1 | 0.0010 | 0.0026 | 7.70E–03 | 1.37E–02 | (4) |
| 7 | 18 wk | 88 | 200 | PET | 2 | 0.0009 | 0.0023 | 3.52E–03 | 4.98E–03 | (1) |
| 8 | 19 wk | 51 | 348 | PET/MRI | 2 | 0.0024 | 0.0063 | 4.10E–03 | 5.72E–03 | (4) |
| 9 | 19 wk | 70 | 296 | PET/MRI | 2 | 0.0037 | 0.0097 | 4.59E–03 | 6.34E–03 | (4) |
| 10 | 21 wk | 53 | 181 | PET/CT | 2 | 0.0049 | 0.0129 | 5.05E–03 | 6.93E–03 | (7) |
| 11 | 23 wk | 59 | 181 | PET | 2 | 0.0078 | 0.0206 | 6.17E–03 | 8.34E–03 | (1) |
| 12 | 25 wk | 67 | 337 | PET | 2 | 0.0084 | 0.0222 | 6.40E–03 | 8.64E–03 | (1) |
| 13 | 25 wk | 76 | 188 | PET/CT | 2 | 0.0156 | 0.0412 | 9.14E–03 | 1.21E–02 | This study |
| 14 | 25 wk | 76 | 188 | PET/CT | 2 | 0.0164 | 0.0434 | 9.46E–03 | 1.25E–02 | This study |
| 15 | 26 wk | 81 | 242 | PET/CT | 2 | 0.0129 | 0.0340 | 8.10E–03 | 1.08E–02 | (9) |
| 16 | 28 wk | 82 | 174 | PET | 3 | 0.0071 | 0.0187 | 3.38E–03 | 3.36E–03 | (1) |
| 17 | ∼28 wk | 66 | 296 | PET | 3 | 0.0195 | 0.0515 | 6.22E–03 | 5.62E–03 | (4) |
| 18 | 30 wk | 89 | 229 | PET | 3 | 0.0196 | 0.0518 | 6.24E–03 | 5.64E–03 | (1) |
| 19 | 34 wk | 95 | 555 | PET/CT | 3 | 0.0192 | 0.0507 | 6.15E–03 | 5.56E–03 | (8) |